Mostrando 10 resultados de: 20
Publisher
Clinical Pharmacology and Therapeutics(3)
European Journal of Clinical Pharmacology(2)
Acta Psychiatrica Scandinavica(1)
Anales de Medicina Interna(1)
British Journal of Clinical Pharmacology(1)
Área temáticas
Farmacología y terapéutica(16)
Enfermedades(12)
Fisiología humana(5)
Bioquímica(4)
Medicina y salud(2)
Origen
scopus(20)
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
ArticleAbstract: In a previous study we showed that the disposition of clozapine after a single oral dose is unrelatePalabras claves:Autores:Adrián LLerena, Alm C., Benitez Rodriguez J., Bertilsson L., Bondesson U., Carrillo J., Dahl M.L., Lindstrom L., Ramos S., Rodriguez de la Rubia I.Fuentes:scopusAssessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
ArticleAbstract: From a sample of 149 unrelated Spaniards, individuals were phenotyped for their ability to hydroxylaPalabras claves:Autores:Adrián LLerena, Avram M., Benitez Rodriguez J., Cobaleda J., Gibbons R., Henthorn T., Krejcie T., Martinez C.Fuentes:scopusDEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquin oxidation polymorphism in a Spanish population
ArticleAbstract: The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measurinPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquine oxidation in schizophrenic patients treated with neuroleptics
ArticleAbstract:Palabras claves:debrisoquine, Neuroleptics, OXIDATION, SchizophreniaAutores:Adrián LLerena, Benitez Rodriguez J., Buemi A.L., Caputi A.P., Cobaleda J., García M.A., Piña B., Spina E.Fuentes:scopusDebrisoquine oxidation phenotype in psychiatric patients.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., García M.A., Martínez C., Piñas B.Fuentes:scopusAcetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusFrequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
ArticleAbstract: We have investigated the prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, heaPalabras claves:caucasian, drug metabolism, Mephenytoin, pharmacogenetics, Phenotype, polymorphismAutores:Adrián LLerena, Benitez Rodriguez J., Bertilsson L., Carrillo J.A., Reviriego J., Valdivielso M.J.Fuentes:scopusMolecular heterogeneity at the CYP2D gene locus in Nicaraguans: Impact of gene-flow from Europe
ArticleAbstract:Palabras claves:CYP2D, Cytochrome p450, Gene-flow, Hispanics, NicaraguansAutores:Adrián LLerena, Agúndez J.A.G., Benitez Rodriguez J., Hernandez M., Ramirez R.Fuentes:scopusOxidative polymorphism of debrisoquine in Parkinson's disease
ArticleAbstract: Oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) have been determined in 87 patienPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Jimenez-Jimenez F.J., Ladero J.M., Martínez C., Muñoz J.J., Puerto A.M., Valdivielso M.J.Fuentes:scopus